Emerging Pharmacotherapies for Androgenetic Alopecia

    June 2026 in “ Expert Opinion on Pharmacotherapy ”
    Akriti Agrawal, Emilee M Dreifus, Antonella Tosti
    Studysummary This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 27

    1. Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Journal of Dermatological Treatment · 2025
    2. Sublingual Minoxidil Increases Fiber Diameter in Male Androgenetic Alopecia: A Proxy for Reversal of Hair Follicle Miniaturization PubMed · 2025
    3. Sublingual Minoxidil 5 mg Versus Oral Minoxidil 5 mg for Male Androgenetic Alopecia: A Double-Blind Randomized Clinical Trial Journal of the European Academy of Dermatology and Venereology · 2024
    4. LB1045 Inhibition of Pyruvate Oxidation Activates Human Hair Follicle Stem Cells Ex Vivo Journal of Investigative Dermatology · 2024
    5. Thyroid Receptor β: A Promising Target for Developing Novel Anti-Androgenetic Alopecia Drugs Drug discovery today · 2024
    6. MTOR Signaling in Hair Follicle and Hair Diseases: Recent Progress Frontiers in medicine · 2023
    7. Signaling by Senescent Melanocytes Hyperactivates Hair Growth Nature · 2023
    8. MTORC1 Activity Negatively Regulates Human Hair Follicle Growth and Pigmentation EMBO reports · 2023
    9. Efficacy of Asymmetric siRNA Targeting Androgen Receptors for the Treatment of Androgenetic Alopecia Molecular Pharmaceutics · 2022
    10. Weekly Treatment with SAMiRNA Targeting the Androgen Receptor Ameliorates Androgenetic Alopecia Scientific Reports · 2022
    11. Efficacy and Safety Profile of Oral Spironolactone Use for Androgenic Alopecia: A Systematic Review PubMed · 2021
    12. Minoxidil: A Comprehensive Review Journal of Dermatological Treatment · 2021
    13. Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Hair Loss, and Hirsutism Actas Dermo-Sifiliográficas · 2020
    14. Efficacy and Safety of Oral Minoxidil in Female Androgenetic Alopecia Dermatologic Therapy · 2020
    15. Safety of Oral Bicalutamide in Female Pattern Hair Loss: A Retrospective Review of 316 Patients Journal of The American Academy of Dermatology · 2020
    16. Oral Bicalutamide for Female Pattern Hair Loss: A Pilot Study Dermatologic Therapy · 2019
    17. A Summary of In Vitro, Phase I, and Phase II Studies Evaluating the Mechanism of Action, Safety, and Efficacy of Clascoterone (Cortexolone 17a Propionate, CB-03-01) in Androgenetic Alopecia Journal of The American Academy of Dermatology · 2019
    18. Lactate Dehydrogenase Activity Drives Hair Follicle Stem Cell Activation Nature cell biology · 2017
    19. A Neutralizing Prolactin Receptor Antibody Whose In Vivo Application Mimics the Phenotype of Female Prolactin Receptor-Deficient Mice Endocrinology · 2015
    20. A Randomized, Active- and Placebo-Controlled Study of the Efficacy and Safety of Different Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia Journal of The American Academy of Dermatology · 2014
    21. The Effectiveness of Finasteride and Dutasteride Used for 3 Years in Women with Androgenetic Alopecia Indian Journal of Dermatology, Venereology and Leprology · 2014
    22. Bald Scalp in Men with Androgenetic Alopecia Retains Hair Follicle Stem Cells but Lacks CD200-Rich and CD34-Positive Hair Follicle Progenitor Cells Journal of Clinical Investigation · 2011
    23. Efficacy, Safety, and Tolerability of Dutasteride 0.5 mg Once Daily in Male Patients with Male Pattern Hair Loss: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Journal of The American Academy of Dermatology · 2010
    24. The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride Journal of The American Academy of Dermatology · 2006
    25. Human Scalp Hair Follicles Are Both a Target and a Source of Prolactin, Which Serves as an Autocrine and/or Paracrine Promoter of Apoptosis-Driven Hair Follicle Regression American Journal of Pathology · 2006
    26. Minoxidil: Mechanisms of Action on Hair Growth British Journal of Dermatology · 2004
    27. A Randomized Clinical Trial of 5% Topical Minoxidil Versus 2% Topical Minoxidil and Placebo in the Treatment of Androgenetic Alopecia in Men Journal of The American Academy of Dermatology · 2002